Provided by Tiger Trade Technology Pte. Ltd.

Daxor

12.28
-0.2100-1.68%
Volume:22.34K
Turnover:278.51K
Market Cap:71.56M
PE:34.05
High:12.70
Open:12.35
Low:12.21
Close:12.49
52wk High:14.76
52wk Low:6.55
Shares:5.83M
Float Shares:2.97M
Volume Ratio:14.94
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3606
EPS(LYR):0.1087
ROE:5.26%
ROA:-2.51%
PB:2.01
PE(LYR):112.97

Loading ...

Daxor initiated with a Buy at Lake Street

TIPRANKS
·
Yesterday

BRIEF-Daxor Corp Reaffirms Focus On Blood Volume Analysis Technology

Reuters
·
Feb 10

Daxor Corp: Announces Transition to Securities Exchange Act of 1934 Reporting Company

THOMSON REUTERS
·
Feb 10

Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business

GlobeNewswire
·
Feb 10

Daxor Files Legal Opinion Affirming Validity of Stock

TIPRANKS
·
Jan 27

Daxor Corporation Announces $9 Million Registered Direct Offering

GlobeNewswire
·
Jan 23

Daxor Releases Updated Investor Presentation to Public Markets

TIPRANKS
·
Jan 23

Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer

GlobeNewswire
·
Nov 25, 2025

Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit

GlobeNewswire
·
Oct 21, 2025

Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25

GlobeNewswire
·
Oct 15, 2025

Daxor Corporation Files Initial Statement of Beneficial Ownership for Chief Medical Officer John Jefferies

Reuters
·
Oct 03, 2025

Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA

GlobeNewswire
·
Sep 30, 2025

Daxor unveils next-gen BVA analyzer at HFSA annual meeting

TIPRANKS
·
Sep 23, 2025

Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting

GlobeNewswire
·
Sep 23, 2025

Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care

GlobeNewswire
·
Sep 04, 2025

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

GlobeNewswire
·
Sep 02, 2025